CCL27 and breast cancer: Studies indicate that ILC1 enhances anti‐tumor responses in murine BC models by interacting with cancer cells and producing IL‐15 and IFNγ, thereby establishing an immune surveillance mechanism against epithelial malignancies [44]; conversely, the infiltration of ILC3 is correlated with BC progression, suggesting that future research may focus on modulating ILC activity to improve immune surveillance and therapeutic outcomes.